Alzheimer's diagnosis used to require a $5,000 brain scan or a painful spinal tap. As of August 2026, the FDA has cleared four blood tests for the disease, from Roche's Elecsys pTau217 to C2N's PrecivityAD2, approved for adults as young as 40.
A single blood draw now confirms or rules out the amyloid plaques behind Alzheimer's. Medicare still won't cover the tests for people without symptoms, and the ASAP Act meant to change that has stalled in Congress. That gap matters because 7.2 million Americans have the disease, and drugs like Leqembi and Kisunla slow it only when started early.
Questions about this story
Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.
No questions yet — be the first to ask.
Key Indicators
7.2M
Americans with Alzheimer's
First time prevalence has exceeded 7 million, with projections reaching 13.8 million by 2060
97.9%
Accuracy ruling out disease
Roche-reported negative predictive value for its Elecsys pTau181 test in the FDA clearance trial of 312 participants
$130
Medicare reimbursement per test
CMS finalized this rate after initially proposing $17, making tests viable for labs that serve patients with symptoms
$384B
Annual cost of Alzheimer's care
Projected to reach nearly $1 trillion by 2050 without medical breakthroughs
4
FDA-cleared blood tests
Fujirebio's Lumipulse (May 2025), Roche's Elecsys pTau181 (Oct 2025), Roche's Elecsys pTau217 and C2N's PrecivityAD2 (both Aug 2026)
50%
Alzheimer's cases undiagnosed
Roughly half of Americans living with Alzheimer's or at risk for it have not been diagnosed, per University of Michigan researchers
Voices
Curated perspectives — historical figures and your fellow readers.
Ever wondered what historical figures would say about today's headlines?
Sign up to generate historical perspectives on this story.
14 events
Latest: July 1st, 2026 · 2 months ago
Showing 8 of 14
JK to step
Tap a bar to jump to that date
Jump to
July 2026
ASAP Act Stalls; Medicare Screening Gap Persists
LatestLegislative
Medicare still does not cover Alzheimer's blood tests for people without symptoms. The ASAP Act, which would create a coverage pathway, has not passed as of mid-2026, leaving patients who want early screening to pay $500 to $1,000 per test out of pocket, per ALZRA.
November 2025
Bipartisan ASAP Act Introduced
Legislative
Congress introduces bill creating Medicare pathway for FDA-cleared blood biomarker screening tests.
October 2025
FDA Clears Roche Test for Primary Care
Regulatory
Elecsys pTau181 becomes first blood test cleared specifically for primary care use, ruling out disease 97.9% of the time.
C2N Submits FDA Application
Regulatory
C2N files first multi-analyte algorithmic blood test using high-resolution mass spectrometry for FDA review.
August 2025
Labcorp Launches Lumipulse Nationwide
Commercial
First FDA-cleared test becomes available at 2,200+ Labcorp patient service centers across United States.
July 2025
Roche Receives European CE Mark
Regulatory
Elecsys pTau181 test receives CE Mark certification, clearing path for European market entry.
May 2025
FDA Clears First Alzheimer's Blood Test
Regulatory
Fujirebio's Lumipulse becomes first FDA-cleared blood test, measuring pTau217/Aβ1-42 ratio with 91.7% positive predictive value.
November 2024
Fujirebio Discovers Manufacturing Issues
Quality
At CTAD conference, Fujirebio identifies problems with commercial lots, placing Lumipulse product on quality hold.
CMS Finalizes $130 Reimbursement Rate
Policy
After proposing just $17, CMS sets $130 Medicare reimbursement, making tests economically viable for labs.
July 2024
FDA Approves Kisunla, Second Anti-Amyloid Drug
Treatment
Donanemab approval intensifies pressure for accessible diagnostics, as drug only works in early-stage disease.
April 2024
Roche-Lilly Test Gets Breakthrough Designation
Regulatory
FDA grants Roche's Elecsys pTau217 test Breakthrough Device designation, expediting review for partnership with Eli Lilly.
July 2023
Quest Launches Controversial Direct-to-Consumer Test
Commercial
Quest introduces direct-to-consumer Alzheimer's blood test, sparking debate about testing without physician guidance.
FDA Approves Leqembi, First Disease-Modifying Drug
Treatment
Lecanemab becomes first therapy proven to slow Alzheimer's cognitive decline, creating urgent need for early diagnostic tools.
January 2018
C2N Receives First Breakthrough Device Designation
Regulatory
FDA grants C2N Diagnostics Breakthrough Device designation for its mass spectrometry-based blood test, beginning the regulatory sprint.
Scenarios
1
Blood Tests Become Standard of Care in Primary Medicine
Likely
Discussed by: Alzheimer's Association, Mayo Clinic researchers, diagnostic industry analysts
With Medicare covering tests at $130 and major labs offering nationwide availability, primary care physicians routinely order blood tests during annual wellness visits for patients over 65. Early detection increases dramatically, catching disease 3-5 years before traditional diagnosis. New drug treatments work better when started early. Deaths from Alzheimer's begin declining for the first time in decades. Additional biomarkers get approved, creating diagnostic panels. The $5,000 brain scan becomes reserved only for ambiguous cases.
2
Quality and Accuracy Issues Undermine Confidence
Possible
Discussed by: ALZFORUM, medical journal editorials, consumer advocacy groups
Manufacturing problems like Fujirebio's quality hold prove systemic across blood test makers. False positives create anxiety and unnecessary follow-up testing. Variations between labs produce inconsistent results. Primary care doctors, lacking dementia expertise, misinterpret findings. High-profile misdiagnosis cases emerge. Medicare restricts coverage pending additional validation. Adoption stalls as specialists question whether tests are ready for widespread use outside research settings.
Quest's direct-to-consumer model expands as competitors follow. Millions of worried middle-aged people order tests without medical supervision. Many receive positive results but lack access to new treatments due to insurance barriers or geographic constraints. Anxiety and depression spike among those testing positive who can't afford $26,500 annual drug costs. Memory clinics overwhelmed with patients seeking confirmatory testing. Regulatory crackdown on direct marketing of tests without physician involvement.
4
New Biomarkers Outpace Current Generation
Uncertain
Discussed by: Nature Medicine researchers, pharmaceutical companies developing diagnostics
Research identifies superior biomarkers beyond pTau217 and pTau181, such as neurofilament light chain or novel inflammatory markers. Next-generation tests combine multiple biomarkers into algorithmic scores with 99%+ accuracy. Companies like C2N gain market advantage with mass spectrometry platforms. First-generation tests from Roche and Fujirebio become obsolete within 3-4 years. Labs face costly equipment upgrades. Early adopters regret infrastructure investments in soon-outdated technology.
5
Two-Tier Alzheimer's Screening Emerges
Possible
Resolves by End of 2026
Discussed by: Alzheimer's Association, health policy researchers, ALZRA
Patients who can pay $500 to $1,000 out of pocket get pre-symptom blood tests and early access to Leqembi or Kisunla. Medicare beneficiaries without that money wait for symptoms, often missing the treatment window. If the ASAP Act fails again, the split widens as private-pay early screening becomes routine for those who can afford it.
Historical Context
3 moments from history that rhyme with this story — and how they unfolded.
1 of 3
1985-1990
HIV Antibody Test Approval (1985)
FDA approved the first blood test detecting HIV antibodies in March 1985, three years after HIV was identified as the cause of AIDS. The test transformed a death sentence into a manageable chronic disease by enabling early treatment. However, initial rollout faced controversy over false positives, stigma, and questions about testing without available treatments.
Then
Testing initially limited to blood banks and high-risk populations, with significant debate over mandatory testing.
Now
Blood testing became routine medical practice, enabling the antiviral revolution that turned HIV into a manageable condition.
Why this matters now
Like HIV testing, Alzheimer's blood tests arrive alongside new treatments (Leqembi, Kisunla) that work best when disease is caught early—but raise similar questions about testing people when treatments aren't universally accessible.
2 of 3
1994-2012
PSA Test for Prostate Cancer (1994)
FDA approved PSA blood testing for prostate cancer screening in 1994, promising early detection through simple blood draws instead of biopsies. Adoption soared. By 2008, most men over 50 were getting regular PSA tests. However, studies revealed widespread overdiagnosis and overtreatment—many men received aggressive treatment for slow-growing cancers that would never have harmed them.
Then
PSA testing became standard of care, with millions of men screened annually and prostate cancer detection increasing sharply.
Now
In 2012, the US Preventive Services Task Force recommended against routine PSA screening after data showed harms outweighed benefits for most men.
Why this matters now
Cautionary tale for Alzheimer's blood tests: early detection isn't always beneficial if treatments are limited, expensive, or carry significant side effects—and if tests generate false positives causing unnecessary anxiety.
3 of 3
2015-2018
Theranos Blood Testing Scandal (2015-2018)
Theranos claimed revolutionary blood testing technology using fingerprick samples, attracting $700 million in investment and partnerships with Walgreens. Investigative journalism revealed the technology didn't work—tests were inaccurate and the company used traditional machines for most analyses. Founder Elizabeth Holmes was convicted of fraud. The scandal traumatized the blood testing industry.
Then
Theranos collapsed, investors lost hundreds of millions, and regulatory scrutiny of diagnostic startups intensified dramatically.
Now
FDA tightened oversight of laboratory-developed tests; investors became cautious about diagnostic companies; public trust in blood testing innovation damaged.
Why this matters now
The Theranos shadow looms over Alzheimer's blood tests—explaining why FDA demanded rigorous validation, why some experts questioned Quest's direct-to-consumer model, and why Fujirebio's manufacturing issues triggered immediate concern.
